Senior Scientist - Remote Target Discovery in Oncology

Tempus AI; Redwood City (CA); Presencial; USD 145 000 - 190 000; Tempo integral

Resumo da oferta

Tempus AI is seeking a Senior Scientist II to advance precision medicine by developing computational methods for drug discovery, leveraging clinico-genomic data and patient-derived organoids, in collaboration with AI/ML teams.

The role requires leadership, strong communication, and the ability to present results to pharma partners; publication activity expected; strong background in genomics and cancer biology.

Qualificações

• PhD in a quantitative field or Life Sciences with strong computational publications.
• 4+ years applying genomic and multimodal data with ML to cancer or complex diseases.
• Proficiency in R, Python, SQL; strong bioinformatics/statistics background.
• Excellent written and verbal communication; ability to lead multidisciplinary projects.
• Leadership experience in cross-functional teams.

Responsabilidades

• Lead translational or real-world evidence research leveraging Tempus multimodal data.
• Collaborate with R&D, product engineering, clinical genomics, and data science teams.
• Communicate plans and findings to internal and external stakeholders; publish abstracts.
• Contribute to peer-reviewed publications and scientific presentations.

Conhecimentos

R, Python, SQL

Genomics, Cancer biology

ML / statistical modeling on genomic数据

Leadership in multidisciplinary proj

Science communication

Formação académica

PhD in Bioinformatics / Computational Biology / Data Science or Life Sciences with computational publications

Ferramentas

Pandas

NumPy

SciPy

Scikit-learn

Jupyter Notebooks

RStudio

tidyverse

ggplot

Git

Docker

AWS

Descrição da oferta de emprego

Tempus AI is seeking a Senior Scientist II to advance precision medicine by developing computational methods for drug discovery, leveraging clinico-genomic data and patient-derived organoids, in collaboration with AI/ML teams.

The role requires leadership, strong communication, and the ability to present results to pharma partners; publication activity expected; strong background in genomics and cancer biology.